re agx, page-10

they bought a biotech company based in china with hep b treatment which has gone through phase III tirals there, ready to market

you could never market it in the west without going through western standard clinical trials but it's good enough for the chinese and se asia - which by the way, the hep b market is huge for!

you should attribute no value to the thrombo rubbish - it's got nothing

plus on top of all that, the chart had the juciest techinical run-up out of a descending wedge

maybe it's the new way for pharma companies?? just put it through chinese standards and sell to asia, excuse the cynicism